Пузырный занос (ПЗ) представляет собой заболевание из ткани трофобласта с сохраненным пролиферативным потенциалом и развивается после аберрантного оплодотворения. Для полного ПЗ характерны быстрое увеличение размеров матки, значительное повышение уровня b-хорионического гонадотропина человека (ХГЧ), кровотечение, симптомы гипертиреоза, тяжелое течение рвоты беременных и раннее развитие преэклампсии. Текалютеиновые кисты формируются в яичниках в результате воздействия высоких титров ХГЧ и пролактина. Многоплодная беременность может осложняться развитием полного и частичного ПЗ у одного из плодов в одном случае на 20 000–100 000 беременностей. В статье представлен клинический случай сопровождения беременной 32 лет с бихориальной биамниотической двойней и полным ПЗ одного плода. Беременность наступила спонтанно, протекала с угрозой прерывания до 12 нед, угрожающими преждевременными родами, преэклампсией с 24 нед. Пациентка была родоразрешена в 28 нед в связи с тяжелой преэклампсией, рождена живая недоношенная девочка массой 1030 г, ростом 33 см с оценкой по шкале Апгар 6/7 баллов. На 40-е сутки после родов уровень b-ХГЧ отрицательный.
Hydatidiform mole (HM) is a disease of trophoblast tissue with saved proliferative potential and it develops after aberrant fertilization. Complete HM is characterized by a rapid increase in a size of the uterus, a significant increase in human b-chorionic gonadotropin (hCG), bleeding, symptoms of hyperthyroidism, severe vomiting of pregnant, and early preeclampsia. Thecalutein cysts are formed in the ovaries as a result of exposure to high titers of hCG and prolactin. Multiple pregnancy may be complicated by the development of complete and partial HM in one of the fetuses in one case for 20 000–100 000 pregnancies. The article presents a clinical case of pregnancy care of a 32-year-old woman with dichorial biamniotic twins and a complete HM of one fetus. Pregnancy occurred spontaneously, proceeded with threatening miscarriage up to 12 weeks, threatened preterm labor, pre-eclampsia from 24 weeks. The patient underwent induction of labor at 28 weeks due to severe pre-eclampsia, a live premature girl with a weight of 1030 g weight, height of 33 cm tall and Apgar score of 6/7 points was born. On the 40th day after birth, b-hCG level was negative.
1. Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol 2013; 128: 3.
2. Altieri A, Franceschi S, Ferlay J et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003; 4: 670.
3. Azuma C, Saji F, Tokugawa Y et al. Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol 1991; 40: 29.
4. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978; 131: 665.
5. Melamed A, Gockley AA, Joseph NT et al. Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol 2016; 143: 73.
6. Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59: 188.
7. Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 2004; 18: 249.
8. Braga A, Moraes V, Maestá I et al. Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women. Int J Gynecol Cancer 2016; 26: 984.
9. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103: 1365.
10. Benson CB, Genest DR, Bernstein MR et al. Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol 2000; 16: 188.
11. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obstet Gynecol 2006; 27: 56.
12. Seckin KD, Baser E, Yeral I et al. The impact of ultrasonographic lesion size and initial human chorionic gonadotropin values on treatment success in cases with complete hydatidiform mole. Eur Rev Med Pharmacol Sci 2013; 17: 3381.
13. Niemann I, Hansen ES, Sunde L. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol 2007; 104: 411.
14. Shazly SA, Ali MK, Abdel Badee AY et al. Twin pregnancy with complete hydatidiform mole and coexisting fetus following ovulation induction with a non-prescribed clomiphene citrate regimen: a case report. J Med Case Rep 2012; 6: 95.
15. Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med 2006; 51: 764.
16. Massardier J, Golfier F, Journet D et al. Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. Eur J Obstet Gynecol Reprod Biol 2009; 143: 84.
17. Niemann L, Fisher R, Sebire NJ et al. Update on UK outcomes for women with twin pregnancies comprising a complete hydatidiform mole and normal co-twin. XVII World Congress on Gestational Trophoblastic Disease. 2013; p. 57 (abstract).
18. Steller MA, Genest DR, Bernstein MR et al. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med 1994; 39: 147.
19. Lin LH, Maestá I, Braga A et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145: 88.
20. Matsui H, Sekiya S, Hando T et al. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Hum Reprod 2000; 15: 608.
21. Tidy JA, Gillespie AM, Bright N et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78: 309.
22. Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007; 52: 397.
23. Elias KM, Shoni M, Bernstein M et al. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med 2012; 57: 254.
24. Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med 2010; 55: 208.
25. Fu J, Fang F, Xie L et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012; 10: CD007289.
26. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001; 46: 110.
27. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009; 105: 3.
28. Adewole IF, Oladokun A, Fawole AO et al. Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole. J Obstet Gynaecol 2000; 20: 68.
29. Feltmate CM, Growdon WB, Wolfberg AJ et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med 2006; 51: 902.
30. Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59: 188.
31. Sebire NJ, Fisher RA, Foskett M et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 2003; 110:
________________________________________________
1. Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol 2013; 128: 3.
2. Altieri A, Franceschi S, Ferlay J et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003; 4: 670.
3. Azuma C, Saji F, Tokugawa Y et al. Application of gene amplification by polymerase chain reaction to genetic analysis of molar mitochondrial DNA: the detection of anuclear empty ovum as the cause of complete mole. Gynecol Oncol 1991; 40: 29.
4. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978; 131: 665.
5. Melamed A, Gockley AA, Joseph NT et al. Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol 2016; 143: 73.
6. Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59: 188.
7. Hershman JM. Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid. Best Pract Res Clin Endocrinol Metab 2004; 18: 249.
8. Braga A, Moraes V, Maestá I et al. Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women. Int J Gynecol Cancer 2016; 26: 984.
9. Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic disease. Obstet Gynecol 2004; 103: 1365.
10. Benson CB, Genest DR, Bernstein MR et al. Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol 2000; 16: 188.
11. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obstet Gynecol 2006; 27: 56.
12. Seckin KD, Baser E, Yeral I et al. The impact of ultrasonographic lesion size and initial human chorionic gonadotropin values on treatment success in cases with complete hydatidiform mole. Eur Rev Med Pharmacol Sci 2013; 17: 3381.
13. Niemann I, Hansen ES, Sunde L. The risk of persistent trophoblastic disease after hydatidiform mole classified by morphology and ploidy. Gynecol Oncol 2007; 104: 411.
14. Shazly SA, Ali MK, Abdel Badee AY et al. Twin pregnancy with complete hydatidiform mole and coexisting fetus following ovulation induction with a non-prescribed clomiphene citrate regimen: a case report. J Med Case Rep 2012; 6: 95.
15. Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome. J Reprod Med 2006; 51: 764.
16. Massardier J, Golfier F, Journet D et al. Twin pregnancy with complete hydatidiform mole and coexistent fetus: obstetrical and oncological outcomes in a series of 14 cases. Eur J Obstet Gynecol Reprod Biol 2009; 143: 84.
17. Niemann L, Fisher R, Sebire NJ et al. Update on UK outcomes for women with twin pregnancies comprising a complete hydatidiform mole and normal co-twin. XVII World Congress on Gestational Trophoblastic Disease. 2013; p. 57 (abstract).
18. Steller MA, Genest DR, Bernstein MR et al. Clinical features of multiple conception with partial or complete molar pregnancy and coexisting fetuses. J Reprod Med 1994; 39: 147.
19. Lin LH, Maestá I, Braga A et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145: 88.
20. Matsui H, Sekiya S, Hando T et al. Hydatidiform mole coexistent with a twin live fetus: a national collaborative study in Japan. Hum Reprod 2000; 15: 608.
21. Tidy JA, Gillespie AM, Bright N et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78: 309.
22. Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007; 52: 397.
23. Elias KM, Shoni M, Bernstein M et al. Complete hydatidiform mole in women aged 40 to 49 years. J Reprod Med 2012; 57: 254.
24. Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med 2010; 55: 208.
25. Fu J, Fang F, Xie L et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012; 10: CD007289.
26. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001; 46: 110.
27. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009; 105: 3.
28. Adewole IF, Oladokun A, Fawole AO et al. Fertility regulatory methods and development of complications after evacuation of complete hydatidiform mole. J Obstet Gynaecol 2000; 20: 68.
29. Feltmate CM, Growdon WB, Wolfberg AJ et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med 2006; 51: 902.
30. Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59: 188.
31. Sebire NJ, Fisher RA, Foskett M et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG 2003; 110:
1. ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2. ГБУЗ «Городская клиническая больница №40» Департамента здравоохранения г. Москвы, Москва, Россия
*katyanikitina@mail.ru
________________________________________________
Iuliia E. Dobrokhotova1, Sergey E. Arakelov2, Sonia Z. Danielyan2, Ekaterina I. Borovkova*1, Sofia A. Zalesskaia1, Margenat K. Medzhidova2, Elena A. Nagaytseva2
1. Pirogov Russian National Research Medical University, Moscow, Russia;
2. City Clinical Hospital №40, Moscow, Russia
*katyanikitina@mail.ru